Penumbra, Inc. (PEN)Healthcare | Medical Devices | Alameda, United States | NYSE
321.68 USD
+0.68
(0.212%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 321.68 |
Hot Take ↕ | Aug. 22, 2026, 2:32 a.m. EDT
Penumbra is a high-quality medical device company with a fortress balance sheet and accelerating revenue growth, yet it trades at a valuation that demands flawless execution. The long-term trajectory is robust, having gained over 260% over nine years without a multi-year decline, and the latest year saw a 34% price surge. However, the short-term picture is mixed; while the stock is trading near its 52-week high, earnings are contracting sharply at -23%, which creates a ceiling on immediate upside. The options market reflects this tension, with traders aggressively buying protection against a downside crash while betting on a recovery to $400. For investors, the business quality supports a long-term hold, but the high price-to-earnings multiple makes it vulnerable to any earnings miss, keeping the short-term outlook cautious despite the technical strength. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.006013 |
| MSTL | 0.006463 |
| AutoTheta | 0.013913 |
| AutoARIMA | 0.033719 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 44% |
| H-stat | 2.70 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.022 |
| Excess Kurtosis | 0.46 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.896 |
| Revenue per Share | 38.364 |
| Market Cap | 12,670,789,632 |
| Trailing P/E | 78.65 |
| Forward P/E | 52.46 |
| Beta | 0.70 |
| Profit Margins | 10.67% |
| Website | https://www.penumbrainc.com |
As of Aug. 22, 2026, 2:32 a.m. EDT: Speculators are pricing in significant downside risk with put implied volatility nearly five times that of calls, indicating a fear of a drop toward the $250-$300 range. Despite this fear, call open interest is concentrated at $350-$400 strikes, suggesting a bullish target range. The heavy put volume at the $300-$310 level acts as a psychological floor, while the high IV skew suggests hedging activity dominates directional speculation.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.19109464 |
| Address1 | One Penumbra Place |
| All Time High | 362.41 |
| All Time Low | 35.315 |
| Ask | 322.79 |
| Ask Size | 160 |
| Audit Risk | 7 |
| Average Analyst Rating | 2.7 - Hold |
| Average Daily Volume10 Day | 270,410 |
| Average Daily Volume3 Month | 361,680 |
| Average Volume | 361,680 |
| Average Volume10Days | 270,410 |
| Beta | 0.701 |
| Bid | 314.5 |
| Bid Size | 120 |
| Board Risk | 5 |
| Book Value | 38.862 |
| City | Alameda |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 321.68 |
| Current Ratio | 5.75 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 322.25 |
| Day Low | 320.83 |
| Debt To Equity | 13.896 |
| Display Name | Penumbra |
| Earnings Call Timestamp End | 1,762,378,200 |
| Earnings Call Timestamp Start | 1,762,378,200 |
| Earnings Growth | -0.235 |
| Earnings Quarterly Growth | -0.231 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 204,282,000 |
| Ebitda Margins | 0.13575 |
| Enterprise To Ebitda | 59.842 |
| Enterprise To Revenue | 8.123 |
| Enterprise Value | 12,224,704,512 |
| Eps Current Year | 4.78747 |
| Eps Forward | 6.13194 |
| Eps Trailing Twelve Months | 4.09 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 320.5024 |
| Fifty Day Average Change | 1.1775818 |
| Fifty Day Average Change Percent | 0.0036741744 |
| Fifty Two Week Change Percent | 19.109463 |
| Fifty Two Week High | 362.41 |
| Fifty Two Week High Change | -40.73001 |
| Fifty Two Week High Change Percent | -0.112386554 |
| Fifty Two Week Low | 221.26 |
| Fifty Two Week Low Change | 100.42 |
| Fifty Two Week Low Change Percent | 0.4538552 |
| Fifty Two Week Range | 221.26 - 362.41 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,442,583,000,000 |
| Float Shares | 38,273,126 |
| Forward Eps | 6.13194 |
| Forward P E | 52.459743 |
| Free Cashflow | 161,100,128 |
| Full Exchange Name | NYSE |
| Full Time Employees | 4,700 |
| Fullday Change | 0.679993 |
| Fullday Change Percent | 0.211836 |
| Fullday Price | 321.68 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.6784 |
| Gross Profits | 1,020,899,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02901 |
| Held Percent Institutions | 0.88365 |
| Implied Shares Outstanding | 39,389,422 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California. |
| Long Name | Penumbra, Inc. |
| Market | us_market |
| Market Cap | 12,670,789,632 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28688621 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 160,588,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,644,004,462 |
| Number Of Analyst Opinions | 12 |
| Open | 320.83 |
| Operating Cashflow | 277,801,984 |
| Operating Margins | 0.105220005 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Peg Ratio | 4.35 |
| Phone | 510 748 3200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 321.68 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 321.0 |
| Price Eps Current Year | 67.19207 |
| Price Hint | 2 |
| Price To Book | 8.277494 |
| Price To Sales Trailing12 Months | 8.419834 |
| Profit Margins | 0.106709994 |
| Quick Ratio | 3.633 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.6875 |
| Region | US |
| Regular Market Change | 0.679993 |
| Regular Market Change Percent | 0.211836 |
| Regular Market Day High | 322.25 |
| Regular Market Day Low | 320.83 |
| Regular Market Day Range | 320.83 - 322.25 |
| Regular Market Open | 320.83 |
| Regular Market Previous Close | 321.0 |
| Regular Market Price | 321.68 |
| Regular Market Time | 1,787,947,202 |
| Regular Market Volume | 234,126 |
| Return On Assets | 0.064169995 |
| Return On Equity | 0.1137 |
| Revenue Growth | 0.149 |
| Revenue Per Share | 38.364 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 4 |
| Shares Outstanding | 39,389,422 |
| Shares Percent Shares Out | 0.0462 |
| Shares Short | 1,818,794 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,123,757 |
| Short Name | Penumbra, Inc. |
| Short Percent Of Float | 0.0531 |
| Short Ratio | 4.91 |
| Source Interval | 15 |
| State | CA |
| Symbol | PEN |
| Target High Price | 374.0 |
| Target Low Price | 323.0 |
| Target Mean Price | 361.83334 |
| Target Median Price | 374.0 |
| Total Cash | 658,795,008 |
| Total Cash Per Share | 16.725 |
| Total Debt | 212,710,000 |
| Total Revenue | 1,504,873,984 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 4.09 |
| Trailing P E | 78.65036 |
| Trailing Peg Ratio | 4.3529 |
| Triggerable | 1 |
| Two Hundred Day Average | 323.1944 |
| Two Hundred Day Average Change | -1.5144043 |
| Two Hundred Day Average Change Percent | -0.004685738 |
| Type Disp | Equity |
| Volume | 234,126 |
| Website | https://www.penumbrainc.com |
| Zip | 94,502 |